Free T4 (fT4) is the unbound, biologically active form of thyroxine—the primary hormone secreted by the thyroid gland. It regulates metabolic rate, energy expenditure, and thermogenesis across virtually every tissue in the body. fT4 is measured directly; total T4 is confounded by thyroid-binding globulin (TBG) fluctuations, so fT4 is the standard.
Analyzed in accredited Swedish clinical laboratories (ISO 15189). Used to support clinician-directed evaluation and monitoring. Not a stand-alone diagnosis.
If you feel persistently fatigued, gain weight without explanation, have cold intolerance, hair loss, or mental fog—or if a routine thyroid screen (TSH) is abnormal—fT4 testing clarifies whether your thyroid is truly dysfunctional or whether the signal is coming from elsewhere. fT4 is the key to distinguishing primary thyroid disease (high fT4, low TSH in hyperthyroidism; low fT4, high TSH in hypothyroidism) from central (pituitary or hypothalamic) dysfunction, where TSH and fT4 move together unexpectedly.
Most people experience at least one significant thyroid shift in their lifetime—pregnancy, menopause, autoimmune activation, iodine deficiency, or stress-driven suppression. fT4 is the direct measure of your thyroid's output capacity, not your body's interpretation of it. That's why it pairs non-negotiably with TSH.
Measures thyroid hormone directly. fT4 bypasses the confounding effects of thyroid-binding globulin (TBG), which fluctuates with estrogen, pregnancy, and hepatic disease. You get the actual hormone concentration in circulation.
Flags central hypothyroidism. When TSH is low or normal but fT4 is low, it signals pituitary or hypothalamic dysfunction—a rare but clinically critical distinction that total T4 or TSH alone would miss.
Clarifies thyroid-replacement adequacy. In patients on levothyroxine, fT4 is the target marker; TSH is indirect and can lag behind biological effect, especially early in treatment or after dose changes.
Contextualizes TSH deviations. A TSH that looks abnormal takes on meaning only with fT4 in hand—elevated TSH with normal fT4 (primary subclinical hypothyroidism) is managed differently from elevated TSH with low fT4 (overt hypothyroidism).
Detects transient thyroid suppression. Severe illness, iodine contrast, amiodarone, or acute stress can suppress fT4 independent of TSH, and fT4 will show it immediately.
Tracks metabolic demand and aging. fT4 naturally drifts upward slightly with age and downward with malnutrition or chronic disease; it's a sensitive proxy for metabolic state.
The hormone, the prohormone, the bound vs. free problem. The thyroid gland synthesizes two main hormones: T4 (thyroxine, ~90% of output) and T3 (triiodothyronine, ~10%). T4 is a prohormone—it has modest biological activity on its own, but its real job is to serve as a stable, circulating reservoir that the body converts to T3 as needed. T3 is the active form. Once T4 enters the bloodstream, roughly 99.9% of it binds tightly to carrier proteins: thyroid-binding globulin (TBG), transthyretin, and albumin. The remaining ~0.1% is free—unbound, available to enter cells, cross cell membranes, and activate thyroid hormone receptors (TR-alpha and TR-beta) inside nuclei and mitochondria. That free fraction is what fT4 measures.
Why the conversion step matters for health and testing. T3 is roughly 3–4 times more potent than T4 at the receptor level. The conversion from T4 to T3 happens peripherally, primarily through deiodinase enzymes in the liver, kidney, muscle, and brain—not in the thyroid itself. This conversion is regulated by energy status, immune activation, illness, selenium and iron availability, and sympathetic nervous system tone. In starvation, illness, or high cortisol, conversion slows dramatically—fT4 can be normal while tissue T3 levels plummet, causing fatigue despite “normal” TSH and fT4. This is why fT4 alone is never enough; it's why TSH, iron (ferritin), and cortisol must contextualize it, and why free T3 sometimes needs measuring in refractory cases.
Thyroid hormone regulates lifespan pathways directly. T3 activates mitochondrial respiration, ATP synthesis, and heat production (thermogenesis)—the core engine of energy expenditure and longevity resilience. Chronic low thyroid state accelerates aging at the cellular level, impairs immune tolerance, and hampers metabolic flexibility.
Identifies hidden metabolic dysfunction. Many people with 'normal' TSH but low fT4 (or high but still-rising fT4) are metabolically compromised—they gain weight despite normal intake, tire easily, or have cold extremities. Standard vårdcentral testing often stops at TSH; catching fT4 deviation early prevents years of misattribution to laziness or aging.
Distinguishes primary from central thyroid disease. A TSH that looks mildly elevated becomes urgent if fT4 is already low; conversely, a low TSH with low-normal fT4 signals pituitary failure and changes the entire diagnostic and therapeutic strategy. fT4 is the only way to make this call.
Guides replacement therapy precision. Levothyroxine monotherapy works for ~80% of primary hypothyroidism patients, but 10–20% require combined T4+T3 therapy or struggle with symptom resolution despite 'normal' TSH ranges. fT4 monitoring (paired with symptoms and reverseT3 or free T3 in complex cases) is how longevity-focused practices fine-tune treatment.
Standard Swedish vårdcentral reference: 9–22 pmol/L (lab-dependent, typically 9–18 pmol/L in modern assays). This range is calibrated to population averages and safety margins; it's not optimized for individual thriving or symptom resolution.
Loovi proactive longevity range: 12–18 pmol/L. Most people feel metabolically resilient, energetic, and capable of temperature regulation within this band. Below 12 pmol/L, fatigue, cold intolerance, and metabolic slowing become common even if TSH remains 'normal'—a pattern called 'mild hypothyroidism' or 'low-T3 syndrome' when T3 is suppressed disproportionately.
Symptomatic hypothyroidism: < 9 pmol/L (confirmed with elevated TSH). Requires treatment initiation.
The critical nuance: fT4 is most meaningful in dialogue with TSH. A fT4 of 10 pmol/L is concerning if TSH is 4.5 mIU/L (primary hypothyroidism developing), but reassuring if TSH is 0.3 mIU/L (central suppression, possibly intentional). Always interpret fT4 as a pair.
Low fT4 (< 9 pmol/L). Reflects underproduction by the thyroid gland or loss of thyroid tissue. If TSH is elevated, primary hypothyroidism (most often autoimmune thyroiditis) is diagnosed; if TSH is low or inappropriately normal, central hypothyroidism (pituitary or hypothalamic failure) is likely. Low fT4 with high cortisol or recent severe illness can also reflect transient suppression from physiological stress. Symptoms include fatigue, weight gain, cold intolerance, constipation, hair loss, and cognitive slowing. Muscle strength and aerobic capacity decline.
Optimal fT4 (12–18 pmol/L with TSH 0.5–2.5 mIU/L). Reflects balanced thyroid output and metabolic stability. Most people in this range report good energy, thermal regulation, and steady body weight. Cognitive function is sharp. This is the target for levothyroxine replacement therapy in hypothyroidism.
High fT4 (> 22 pmol/L). Reflects thyroid overproduction (Graves' disease, toxic nodules, thyroiditis) or excess exogenous hormone (over-replacement on levothyroxine, factitious hyperthyroidism from self-administration, or iodine excess). If TSH is suppressed (< 0.1 mIU/L), thyrotoxicosis is present. Symptoms include palpitations, tremor, heat intolerance, anxiety, insomnia, weight loss despite good appetite, and proximal muscle weakness. Bone loss accelerates and atrial fibrillation risk rises.
Factors that influence fT4. Estrogen (oral contraceptives, hormone therapy) increases TBG, potentially lowering measured fT4 transiently; pregnancy does the same. Biotin supplementation (> 2.5 mg/day) can interfere with immunoassays, artefactually raising or lowering fT4. Heparin (unfractionated, not LMWH) can displace thyroid hormone from binding proteins, causing acutely elevated fT4 in-hospital. Severe nonthyroidal illness (sepsis, burns, critical illness) suppresses fT4 and TSH together. Recent iodine contrast exposure (CT, angiography) can cause transient thyroid suppression. Amiodarone (highly iodine-rich) causes variable thyroid dysfunction.
Autoimmune thyroid disease (primary hypothyroidism). Hashimoto's thyroiditis (anti-TPO and anti-thyroglobulin antibodies) is the most common cause of hypothyroidism in iodine-sufficient regions, including Sweden. The immune system attacks thyroid tissue, reducing hormone synthesis. Prevalence increases with age, female sex, and other autoimmune conditions (celiac, type 1 diabetes, pernicious anemia).
Iodine deficiency or excess. The thyroid requires dietary iodine to synthesize T4 and T3. Deficiency (rare in Sweden due to iodized salt, but can occur in strict vegan diets) lowers fT4; excess (from supplements, seaweed, or contrast agents) can transiently suppress the gland via the Wolff-Chaikoff effect, causing fT4 to drop.
Pituitary or hypothalamic dysfunction. Tumors, surgery, radiation, trauma, or infiltrative disease (sarcoidosis, hemochromatosis) can impair TSH secretion, resulting in low fT4 with low-normal or low TSH. This is central hypothyroidism and requires different treatment than primary disease.
Medications and lifestyle. Lithium inhibits thyroid hormone release and iodine uptake. Beta-blockers, glucocorticoids at high doses, and interferon-alpha can suppress fT4. Stress elevates cortisol, which blunts TSH and can suppress fT4 via altered deiodinase activity and increased reverse T3 (inert, competes for T3 receptor). Starvation and extreme weight loss suppress fT4 profoundly.
Age and female sex. fT4 drifts downward slightly with aging (roughly 1 pmol/L per decade after 50), possibly reflecting gradual thyroid atrophy. Women have higher TSH and lower fT4 on average than men, and postmenopausal women show further decline in fT4.
Ensure adequate iodine intake. Iodine is the raw material; without sufficient intake (≈ 150 µg/day, higher in pregnancy), thyroid hormone synthesis cannot proceed. Swedish table salt is iodized, but vegans consuming only whole foods may fall short. Seaweed is high in iodine but variable and can cause excess; fish and eggs are reliable sources.
Optimize nutritional cofactors for conversion. T4→T3 conversion depends on selenium (deiodinase cofactor; target 100–200 µg/day from foods like fish, eggs, nuts), iron (ferritin > 40 ng/mL supports conversion; deficiency stalls it), and zinc. Vitamin B12 and folate also support thyroid metabolism. A chronically depleted micronutrient state will depress fT4 and T3 conversion regardless of TSH.
Reduce chronic physiological stress. High cortisol, poor sleep, or sustained training stress elevate reverse T3 (the inactive metabolite) and suppress conversion of T4 to T3, creating functional hypothyroidism despite normal fT4. Sleep, walking, and cortisol regulation are primary levers.
In primary hypothyroidism, replace T4 with levothyroxine. Levothyroxine is an oral synthetic T4; the body converts it peripherally to T3 as needed. Typical doses are 25–200 µg/day, titrated so that TSH and fT4 reach target ranges and symptoms resolve. Most people stabilize on one dose; changes take 4–6 weeks to fully equilibrate. Absorption is improved on an empty stomach (1 hour before food), and it should be separated from iron, calcium, and biotin supplements.
Consider combined T4+T3 therapy in refractory cases. ~10–20% of patients with primary hypothyroidism remain symptomatic on levothyroxine monotherapy despite normal fT4 and TSH. This may reflect inadequate peripheral conversion (elevated reverse T3, low free T3, genetic variation in deiodinase), and combined therapy—adding small doses of synthetic liothyronine (T3)—can restore symptom resolution. This is not first-line, but fT4 and free T3 monitoring guides the decision.
The right intervention depends on the individual's genetics, metabolic state, nutritional baseline, and full thyroid panel (TSH, fT4, free T3, reverse T3, anti-TPO antibodies, ferritin, cortisol). This is precisely where a Loovi longevity doctor assessment clarifies the path.
fT4 is half a story. A fT4 of 10 pmol/L means something entirely different if TSH is 5 mIU/L (primary hypothyroidism) versus 0.2 mIU/L (central hypothyroidism or intentional suppression). Similarly, a normal fT4 with elevated TSH signals early autoimmune thyroiditis and rising risk of overt disease; catching it now allows preventive intervention (nutrient optimization, inflammation reduction) before symptoms emerge.
Context requires TSH always, and often more. If fT4 and TSH are discordant, or if symptoms persist despite 'normal' results, free T3 and reverse T3 reveal whether the conversion step is broken. Ferritin, cortisol, and anti-TPO antibodies shape interpretation further. A Loovi longevity program tracks all of these—120+ biomarkers annually, including thyroid function, metabolic markers (HbA1c, fasting insulin), inflammation (hs-CRP), nutrient status (ferritin, vitamin D, B12), and adrenal function (cortisol)—paired with unrushed doctor consultations where nuance becomes personalized action.
This pattern—normal fT4 with TSH > 2.5 mIU/L—is subclinical hypothyroidism. Your thyroid is working harder (high TSH) to maintain normal fT4 output, suggesting early thyroid reserve depletion, often from autoimmune attack. Many people with this pattern are asymptomatic, but risk of progression to overt hypothyroidism (low fT4 + high TSH) is real over years. If anti-TPO antibodies are positive, the risk is higher. Loovi's approach monitors TSH and fT4 trends—even 1–2 pmol/L drops in fT4 year-over-year signal thyroid decline worth addressing proactively with micronutrient support and inflammation reduction before replacement therapy becomes necessary.
Yes. Levothyroxine dosing is titrated so that both TSH and fT4 reach targets simultaneously—typically TSH 0.5–2.5 mIU/L and fT4 12–18 pmol/L. Starting doses are usually 25–50 µg/day; increases of 25 µg/day happen every 4–6 weeks until targets are met. Overtreatment (fT4 > 20 pmol/L with TSH suppressed) causes iatrogenic hyperthyroidism—bone loss, atrial fibrillation, and accelerated aging. Undertreatment (fT4 < 10 pmol/L with high TSH) perpetuates fatigue and metabolic slowing. fT4 is the direct measure of dose adequacy; TSH lags and is unreliable early in therapy.
Absolutely. In health, roughly 80% of circulating T3 comes from peripheral conversion of T4; the remaining 20% is secreted directly by the thyroid. But conversion can fail—high reverse T3 (from stress, illness, low iron), low selenium, or genetic deiodinase variation all reduce T4→T3 conversion. You can have normal fT4 but low fT3, causing fatigue, cold intolerance, and stubborn weight despite adequate thyroid hormone ‘on paper.’ This is why doctors who obsess over TSH alone miss the picture. Free T3 and reverse T3 testing are worth exploring if fT4 and TSH are normal but symptoms persist.
Most vårdcentraler reflex to fT4 testing once TSH is out of range—so if your TSH is abnormal, fT4 is ordered automatically. But if your TSH is 'normal' and you want fT4 checked (to assess metabolic reserve, detect early thyroid decline, or troubleshoot fatigue), you may need to request it or access a private longevity service. Loovi includes fT4 as part of annual thyroid profiling for all members.
fT4 begins rising within days of starting levothyroxine, but the full equilibrium takes 4–6 weeks because the drug accumulates in body pools and the body's peripheral conversion of the new T4 to T3 requires time to upregulate. Symptoms may lag even longer—fatigue and weight loss often take 8–12 weeks to reverse completely. Retesting fT4 before 4 weeks is premature and risks unnecessary dose escalation. After stabilization, fT4 typically remains stable on a constant dose indefinitely, but annual monitoring catches dose drift (from altered absorption, intestinal changes, or age-related clearance shifts).
fT4 is remarkably stable within the day—it doesn't have a pronounced circadian rhythm like cortisol or TSH (which peaks early morning). Fasting vs. fed doesn't matter significantly, though levothyroxine should always be taken on an empty stomach for consistent absorption. If you're on levothyroxine, test in the morning (at trough, before the next dose) so results are comparable over time. Biotin supplements (> 2.5 mg/day) can interfere with assays, so disclose that to your lab.
Rising fT4 over time on a static dose can signal over-replacement (absorption has improved, or dosing was already too high and it took time to accumulate). It can also reflect thyroid recovery if you started levothyroxine for transient thyroiditis or stress-induced suppression rather than permanent primary disease—your own thyroid is recovering and the exogenous hormone is piling on top. Check TSH; if it's suppressed (< 0.3 mIU/L), reduce the levothyroxine dose by 12.5–25 µg. If TSH is normal but fT4 continues rising, explore whether there's underlying hyperthyroidism (Graves', toxic nodules) being masked by the levothyroxine.
Pregnancy increases TBG dramatically (from estrogen), so total T4 rises sharply—but free fT4 is actually more stable. However, pregnancy increases basal metabolic rate and TSH suppression can occur. If you're on levothyroxine before pregnancy, you typically need 25–50% dose increases by the second trimester to keep fT4 and TSH in range (TSH < 2.5 mIU/L in first trimester, < 3.0 mIU/L thereafter, per European guidelines). Retest fT4 and TSH every 6–8 weeks during pregnancy, especially early. After delivery, doses usually drop back to pre-pregnancy levels within weeks.
In severe acute illness—sepsis, trauma, cardiac or respiratory failure—thyroid hormone metabolism shifts dramatically. fT4 often falls despite TSH remaining normal or low (nonthyroidal illness syndrome), and conversion to T3 is suppressed. This was once thought protective (lowering metabolic demand), but it's now recognized as a sign of poor prognosis. fT4 testing in the ICU can flag severe sickness; the pattern doesn't warrant replacement therapy, but it signals that the body is profoundly stressed. Recovery usually restores thyroid function once the acute illness resolves.
